1
|
Roncolato F, O'Connell R, Joly F, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Salutari V, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Fehm T, Ledermann J, Roemer-Becuwe C, Stockler M, King M, Friedlander M. Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS). Gynecol Oncol 2020; 156:45-53. [DOI: 10.1016/j.ygyno.2019.10.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Revised: 09/27/2019] [Accepted: 10/03/2019] [Indexed: 11/24/2022]
|
2
|
Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, Suzuki M. A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. Jpn J Clin Oncol 2010; 41:278-82. [DOI: 10.1093/jjco/hyq182] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
3
|
Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, Numa F, Okada M, Aotani E, Terakawa N. Comparative phase II study of intraperitoneal (IP) versus intravenous (IV) carboplatin administration with IV paclitaxel in patients with bulky residual disease after primary debulking surgery for epithelial ovarian or primary peritoneal cancer: A Sankai Gynecology Study Group (SGSG) study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5584 Background: To assess the anti-tumor effect and safety of IP carboplatin (C) administration comparing with IV C administration in combination with IV infusion of paclitaxel (P). Methods: This is a non-randomized comparative phase II trial. Eligible patients were those with histologically confirmed epithelial ovarian or primary peritoneal cancer who received initial surgery and ended up with residual disease >= 2 cm. They must have reasonable hematological, hepatic, renal function before receiving chemotherapy. The patients received either of the following treatment arms; IP Arm: IV P 175 mg/m2 over 3h followed by IP C AUC6, IV Arm: IV P 175 mg/m2 over 3h followed by IV C AUC6. The treatments were scheduled to repeat 6–8 cycles. Interval debulking surgery was allowed after 3 to 5 cycle of treatment. Each participating institution had to declare, before the study was opened, which of the treatment arms the patients from the institution would be entered. Primary endpoint was a response. Secondary endpoints were toxicity and progression-free survival (PFS) and overall survival (OS). Target accrual was 30 patients in each arm. Results: Total accrual was 26 patients for IP arm and 30 patients for IV arm between 2001 and 2005. The study was closed early, because of the conflict of protocols for IP treatment. Eligible patients were 24 in IP Arm and 25 for IV arm. Median number of treatment cycle was 6 for both arms. Although the difference was not statistically significant, response rate was better in the IP Arm. Response rates were 83.3% (95%CI: 62.6%-95.3%) for IP Arm and 60.0% (95%CI: 38.7%-78.9%) for IV Arm. As of median followup of 31 months, median PFS is 25 months for IP Arm and 21 months for IV Arm,. Median OS is not reached for IP Arm, and 52 months for IV arm. Incidences of hematological and non-hematological toxicities were essentially the same on both arms. Conclusions: IP administration of C may be a better treatment strategy for epithelial ovarian and primary peritoneal cancer patients. A randomized phase III trial including bulky residual disease for comparison of IP and IV carboplatin treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Fujiwara
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - S. Nagao
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - J. Kigawa
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - J. Noma
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - N. Akamatsu
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - Y. Miyagi
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - F. Numa
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - M. Okada
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - E. Aotani
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - N. Terakawa
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| |
Collapse
|
4
|
Nagao S, Fujiwara K, Kagawa R, Kozuka Y, Oda T, Maehata K, Ishikawa H, Koike H, Aotani E, Kohno I. Is the adjustment of serum creatinine level < 0.6 mg/dl to 0.6 mg/dl justified in estimates of carboplatin clearance calculated by the Jelliffe formula? J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5072 Background: The Jelliffe formula (JF) does not include body surface area (BSA) or body weight to adjust the body size. We demonstrated that estimates of carboplatin clearance calculated by the JF tend to have greater positive bias compared to other formulae. The JF has been used to estimate carboplatin clearance in Gynecologin Oncology Group studies. In patients with serum creatinine level <0.6 mg/dl, it is adjusted to 0.6 mg/dl in estimates of carboplatin clearance (Adjusted-Jelliffe formula (AJF)). The purpose of this study is to evaluate whether this adjustment is suitable. Methods: Carboplatin clearance was estimated in 115 patients with serum creatinine <0.6 mg/dl who received carboplatin-based chemotherapy for gynecologic malignancies between January 1996 and August 2004. Creatinine clearance was estimated using the Cockroft-Gault formula (CGF), JF, and AJF. The median percent error (MPE) and the median absolute percent error (MAPE) were evaluated by comparing carboplatin clearance. The relationships between BSA and ratios of estimated carboplatin clearance (JF/CGF, AJF/CGF) were evaluated by using simple regression. Results: The estimated carboplatin clearances were: CGF, 126.7 ± 27.7; JF, 148.2 ± 20.5; AJF, 130.5 ± 14.3. Comparing the results of the CGF with the JF, AJF yielded MPEs of +20%, +6%, and MAPEs of 21%, 14%, respectively. There were the linear correlations between ratio of estimated carboplatin clearances and BSA (Y1 = −1.141X + 2.830, Y2 = -1.061 X + 2.581, Y1: ratio of carboplatin clearance (JF/CGF), Y2: ratio of carboplatin clearance (AJF/CGF), X: BSA). Conclusions: As expected, carboplatin clearance was decreased by adjusting serum creatinine to 0.6 mg/ml, but it did not adjust the bias by BSA. Estimates of carboplatin clearance calculated by the AJF tend to have greater negative bias, particularly when the BSA of the patient is large. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Nagao
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| | - K. Fujiwara
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| | - R. Kagawa
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| | - Y. Kozuka
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| | - T. Oda
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| | - K. Maehata
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| | - H. Ishikawa
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| | - H. Koike
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| | - E. Aotani
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| | - I. Kohno
- Kawasaki Medical School, Kurashiki City, Okayama, Japan; Kitasato Institute, Tokyo, Japan
| |
Collapse
|
5
|
Fujiwara K, Sugiyama T, Aotani E, Kigawa J, Kuzuya K, Saji F, Ochiai K, Noda K. Pattern of care study for treatment of ovarian cancer patients among Japanese gynecologists. A Japanese Gynecologic Oncology Group (JGOG) study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.15029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15029 Background: The Japanese Society of Gynecologic Oncology started a training program for the subspecialty of board certified gynecologic oncologists in 2005. This study aimed to assess the attitude of Japanese gynecologists for the treatment of ovarian cancer in pre-gynecologic oncologist era. Methods: The JGOG distributed a survey to 217 member institutions in January 2005. The principal investigator (PI) of each institution answered 33 questionnaires regarding diagnostic, surgical and chemotherapy issues. The survey was returned from 156 institutions (71.9%). Results: Hospital settings were general (44%), academic (44%), Cancer Center (8%), or private (4%). Only two of PIs were medical oncologists and rests of them were gynecologists. As the staging procedure in early ovarian cancer, 67% institutions do systemic pelvic lymphadenectomy (LNX) but 22% do only sampling. For the paraaortic nodes, 36% do systemic LNX and 10% do sampling below renal vein, and 14% do LNX and 12% do sampling below inferior mesenteric artery. However, intraabdominal explorations such as multiple peritoneal biopsies have been done only less than 30% except for omentectomy (90%). With regard to the surgery for advanced ovarian cancer, 57% institutions do not do any intestinal resection and anastomosis during the primary surgery. Among them 7% of institutions prefer neoadjuvant chemotherapy (no debulking at all) for advanced ovarian cancer. However, 84% of the institutions do interval debulking and 57% of them are quite aggressive for the procedure. These results demonstrate the high expectation that chemotherapy may reduce the aggressiveness of surgery for advanced ovarian cancer. In terms of chemotherapy for the high-risk early and advanced ovarian cancer, taxane plus platinum is the most used regimen (93–95%). However, 45% of institutions prefer different regimen for clear cell carcinoma. CPT-11 is the most used (88.6%). Intraperitoneal chemotherapy has been performed in 28.2% of institutions. 37.2% of institutions do consolidation chemotherapy. Conclusions: This is an important base-line information to assess the pattern of care for ovarian cancer patients in the era before gynecologic oncologist subspecialty is applicable in Japan. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Fujiwara
- Kawasaki Medical School, Kurashiki City, Japan; Iwate Medical University, Morioka, Japan; Kitasato Institute, Tokyo, Japan; Tottori University, Yonago, Japan; Kuzuya Clinic, Nagoya-City, Japan; Kure Medical Center, Kure-City, Japan; Jikei University School of Medicine, Tokyo, Japan; Kinki University, Osaka-Sayama-City, Japan
| | - T. Sugiyama
- Kawasaki Medical School, Kurashiki City, Japan; Iwate Medical University, Morioka, Japan; Kitasato Institute, Tokyo, Japan; Tottori University, Yonago, Japan; Kuzuya Clinic, Nagoya-City, Japan; Kure Medical Center, Kure-City, Japan; Jikei University School of Medicine, Tokyo, Japan; Kinki University, Osaka-Sayama-City, Japan
| | - E. Aotani
- Kawasaki Medical School, Kurashiki City, Japan; Iwate Medical University, Morioka, Japan; Kitasato Institute, Tokyo, Japan; Tottori University, Yonago, Japan; Kuzuya Clinic, Nagoya-City, Japan; Kure Medical Center, Kure-City, Japan; Jikei University School of Medicine, Tokyo, Japan; Kinki University, Osaka-Sayama-City, Japan
| | - J. Kigawa
- Kawasaki Medical School, Kurashiki City, Japan; Iwate Medical University, Morioka, Japan; Kitasato Institute, Tokyo, Japan; Tottori University, Yonago, Japan; Kuzuya Clinic, Nagoya-City, Japan; Kure Medical Center, Kure-City, Japan; Jikei University School of Medicine, Tokyo, Japan; Kinki University, Osaka-Sayama-City, Japan
| | - K. Kuzuya
- Kawasaki Medical School, Kurashiki City, Japan; Iwate Medical University, Morioka, Japan; Kitasato Institute, Tokyo, Japan; Tottori University, Yonago, Japan; Kuzuya Clinic, Nagoya-City, Japan; Kure Medical Center, Kure-City, Japan; Jikei University School of Medicine, Tokyo, Japan; Kinki University, Osaka-Sayama-City, Japan
| | - F. Saji
- Kawasaki Medical School, Kurashiki City, Japan; Iwate Medical University, Morioka, Japan; Kitasato Institute, Tokyo, Japan; Tottori University, Yonago, Japan; Kuzuya Clinic, Nagoya-City, Japan; Kure Medical Center, Kure-City, Japan; Jikei University School of Medicine, Tokyo, Japan; Kinki University, Osaka-Sayama-City, Japan
| | - K. Ochiai
- Kawasaki Medical School, Kurashiki City, Japan; Iwate Medical University, Morioka, Japan; Kitasato Institute, Tokyo, Japan; Tottori University, Yonago, Japan; Kuzuya Clinic, Nagoya-City, Japan; Kure Medical Center, Kure-City, Japan; Jikei University School of Medicine, Tokyo, Japan; Kinki University, Osaka-Sayama-City, Japan
| | - K. Noda
- Kawasaki Medical School, Kurashiki City, Japan; Iwate Medical University, Morioka, Japan; Kitasato Institute, Tokyo, Japan; Tottori University, Yonago, Japan; Kuzuya Clinic, Nagoya-City, Japan; Kure Medical Center, Kure-City, Japan; Jikei University School of Medicine, Tokyo, Japan; Kinki University, Osaka-Sayama-City, Japan
| |
Collapse
|
6
|
Nagao S, Fujiwara K, Ishikawa H, Oda T, Tanaka K, Aotani E, Kohno I. Hormonal function after ovarian transposition to the abdominal subcutaneous fat tissue. Int J Gynecol Cancer 2006; 16:121-4. [PMID: 16445621 DOI: 10.1111/j.1525-1438.2006.00280.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
We previously reported a new technique for ovarian transposition to the abdominal subcutaneous fat tissue (OTAFT) following hysterectomy. The purpose of this study is to assess the hormonal function after OTAFT. From 1993 to 2000, OTAFT was performed in 27 patients (group A). Forty-two women underwent hysterectomy and retained ovaries without transposition (group B). In 19 cases, bilateral oophorectomy with hysterectomy was performed, and they received a hormone replacement therapy (HRT) (group C). Serum follicle-stimulating hormone (FSH) level of patients was monitored every 2-12 months, and the time of menopause (defined as FSH >40 mIU/mL two times consecutively) was determined in groups A and B. After a median follow-up of 65 months, cumulative ovarian survival did not show significant difference between group A and group B (HR = 0.52, 95% CI = 0.17-1.16; P= 0.10). In patients who were 40 years old or younger, ovarian function declined significantly in group A compared to group B (HR = 0.29, 95% CI = 0.02-0.91; P= 0.04). However, FSH level of postmenopausal patients in group A was not different from FSH level of patients in group C, but FSH level of postmenopausal patients in group B was significantly higher than FSH level of patients in group C (P= 0.002). Although the procedure of OTAFT may somewhat affect the ovarian function, the transposed ovary in postmenopausal women presumably still secrete a small amount of estrogen which is equivalent to an estrogen level by HRT.
Collapse
Affiliation(s)
- S Nagao
- Department of Obstetrics and Gynecology, Kawasaki Medical School, 577 Matsushima, Kurashiki-City 701-0192, Japan
| | | | | | | | | | | | | |
Collapse
|
7
|
Fujiwara K, Suzuki S, Ishikawa H, Oda T, Aotani E, Kohno I. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int J Gynecol Cancer 2005; 15:426-31. [PMID: 15882165 DOI: 10.1111/j.1525-1438.2005.15304.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The objective of this study was to provide preliminary toxicity data of multiple-cycle combination chemotherapy with intraperitoneal (IP) carboplatin and intravenous (IV) paclitaxel for further clinical trials. The toxicity data of 42 patients with mullerian carcinoma who underwent IP carboplatin therapy in combination with IV paclitaxel were retrospectively analyzed. Chemotherapy was repeated through the Bard IP port placed at initial surgery using IV paclitaxel at 175 mg/m2 followed by IP carboplatin. The doses of carboplatin were either at area under the curve (AUC) = 5, 6, 6.5, 7, or 7.5. The toxicity data in a total of 237 cycles were analyzed. The median number of cycles for IP chemotherapy was 6 (range: 3-12). The incidences of maximal grade toxicities in all cycles were: grade (G)2/3 nausea/vomiting, 23.8%; G2/3 constipation, 42.9%; G2 abdominal pain, 28.6%; G2/3 sensory neuropathy, 14.3%; motor neuropathy, 4.8%; myalgia/arthralgia 33.4%; G3/4 neutrocytopenia, 85.4%; and G3/4 anemia, 35.4%. These were not related to the dose of carboplatin. The incidences of G3 thrombocytopenia in relation to the dose of carboplatin were AUC = 5, 0%; 6, 31.6%; 6.5, 44.4%; 7, 25.0%; and 7.5, 80%. G4 thrombocytopenia did not occur. A dose of carboplatin between AUC = 6 and 7 with IV paclitaxel at 175 mg/m2 is warranted for further evaluation.
Collapse
Affiliation(s)
- K Fujiwara
- Department of Obstetrics and Gynecology, Kawasaki Medical School, Kurashiki City, Japan
| | | | | | | | | | | |
Collapse
|
8
|
Fujiwara K, Suzuki S, Ishikawa H, Oda T, Aotani E, Kohno I. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int J Gynecol Cancer 2005. [DOI: 10.1136/ijgc-00009577-200505000-00003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
The objective of this study was to provide preliminary toxicity data of multiple-cycle combination chemotherapy with intraperitoneal (IP) carboplatin and intravenous (IV) paclitaxel for further clinical trials. The toxicity data of 42 patients with müllerian carcinoma who underwent IP carboplatin therapy in combination with IV paclitaxel were retrospectively analyzed. Chemotherapy was repeated through the Bard IP port placed at initial surgery using IV paclitaxel at 175 mg/m2 followed by IP carboplatin. The doses of carboplatin were either at area under the curve (AUC) = 5, 6, 6.5, 7, or 7.5. The toxicity data in a total of 237 cycles were analyzed. The median number of cycles for IP chemotherapy was 6 (range: 3–12). The incidences of maximal grade toxicities in all cycles were: grade (G)2/3 nausea/vomiting, 23.8%; G2/3 constipation, 42.9%; G2 abdominal pain, 28.6%; G2/3 sensory neuropathy, 14.3%; motor neuropathy, 4.8%; myalgia/arthralgia 33.4%; G3/4 neutrocytopenia, 85.4%; and G3/4 anemia, 35.4%. These were not related to the dose of carboplatin. The incidences of G3 thrombocytopenia in relation to the dose of carboplatin were AUC = 5, 0%; 6, 31.6%; 6.5, 44.4%; 7, 25.0%; and 7.5, 80%. G4 thrombocytopenia did not occur. A dose of carboplatin between AUC = 6 and 7 with IV paclitaxel at 175 mg/m2 is warranted for further evaluation.
Collapse
|
9
|
Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I. Development of a mathematical model of intraperitoneal/intravenous infusion of carboplatin. A Sankai Gynecology Study Group study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Y. Miyagi
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - K. Fujiwara
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - J. Kigawa
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - H. Itamochi
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - S. Nagao
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - E. Aotani
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - N. Terakawa
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - I. Kohno
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| |
Collapse
|